UCSF Center for HIV Information

University of California, San Francisco

1700 Owens Street, Suite 316
San Francisco, CA 94158
United States

Articles: 49

Title Publish date Review date
Accessibility: The Bigger Picture
TargetHIV: New Name, New Look
Tissue Levels of TAF: Too Low for PrEP?
Switching from TDF/FTC to TAF/FTC
PrEP: Bone Density Improves after Stopping TDF/FTC
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
HIV Meds Update - RAPID: Immediate ART Initiation
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
CROI 2017: Failure of Dolutegravir Monotherapy
CROI 2017: Dolutegravir in 2-Drug Simplification Studies
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment
Bictegravir in Initial Therapy
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
Ibalizumab Approved for Persons with Multidrug Resistant HIV
Naltrexone Improves Virologic Suppression
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
Immediate ART Initiation Improves Time to Viral Suppression
Bictegravir/TAF/FTC in Women
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
Dolutegravir + 3TC in Initial Therapy
U=U in PARTNER2 Study of MSM
Doravirine--New NNRTI Approved by FDA
Rapid ART Start
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
Safety of Dolutegravir at Conception: Updated Data
New ARV Approval - Fostemsavir
Long-acting Injectable PrEP: Cabotegravir
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
Long-acting Injectable PrEP Approved: Cabotegravir
Updated CDC PrEP Guidelines
HIV Meds Update: Anal Dysplasia Treatment Prevents Anal Cancer - The ANCHOR Study
FDA Approves Lenacapavir, New Long-Acting Injectable ARV
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Use of Dolutegravir in Dialysis
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects